| Revision as of 21:50, 18 February 2019 edit108.35.217.152 (talk) →References← Previous edit |
Revision as of 19:21, 27 March 2020 edit undoBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,738 edits consistent citation formattingNext edit → |
| Line 31: |
Line 31: |
|
| molecular_weight = 12,103 g/mol (protein part) |
|
| molecular_weight = 12,103 g/mol (protein part) |
|
}} |
|
}} |
|
'''Pegsunercept''' is a ] for the treatment of ]. {{As of|2010|1}}, Phase II ]s have been completed.<ref>{{ClinicalTrialsGov|NCT00037700|Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis}}</ref><ref>{{ClinicalTrialsGov|NCT00111423|Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)}}</ref><ref name="Furst">{{Cite journal |
|
'''Pegsunercept''' is a ] for the treatment of ]. {{As of|2010|1}}, Phase II ]s have been completed.<ref>{{ClinicalTrialsGov|NCT00037700|Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis}}</ref><ref>{{ClinicalTrialsGov|NCT00111423|Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)}}</ref><ref name="Furst">{{cite journal | vauthors = Furst DE, Fleischmann R, Kopp E, Schiff M, Edwards C, Solinger A, Macri M | title = A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis | journal = The Journal of Rheumatology | volume = 32 | issue = 12 | pages = 2303–10 | date = December 2005 | pmid = 16331754 }}</ref> It is being developed by ]. |
|
| last6 = Solinger |
|
|
| pmid = 16331754 |
|
|
| last5 = Edwards C |
|
|
| journal = The Journal of Rheumatology |
|
|
| last7 = Macri |
|
|
| issue = 12 |
|
|
| last8 = 990136 Study |
|
|
| pages = 2303–2310 |
|
|
| volume = 32 |
|
|
| last4 = Schiff |
|
|
| last2 = Fleischmann |
|
|
| title = A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis |
|
|
| last3 = Kopp |
|
|
| last1 = Furst |
|
|
| year = 2005 | first1 = D. | first2 = R. | first3 = E. | first4 = M. | first5 = 3. | first6 = A. | first7 = M. | first8 = G. |
|
|
}}</ref> It is being developed by ]. |
|
|
|
|
|
|
Similarly to ], pegsunercept is a soluble ]. Pegsunercept is a ] protein.<ref name="Furst" /> |
|
Similarly to ], pegsunercept is a soluble ]. Pegsunercept is a ] protein.<ref name="Furst" /> |
|
|
|
|
|
==References== |
|
== References == |
|
{{Reflist}} |
|
{{Reflist}} |
|
|
|
|
| Line 60: |
Line 44: |
|
] |
|
] |
|
] |
|
] |
|
|
|
|
|
|
|
|
{{antineoplastic-drug-stub}} |
|
{{antineoplastic-drug-stub}} |
